Acasunlimab · GEN-1046

What is Acasunlimab?

Acasunlimab is a bispecific antibody that binds PD-L1 on tumor cells and 4-1BB (CD137) on leukocytes, including activated T lymphocytes. It blocks PD-L1 from engaging PD-1 and acts as a conditional 4-1BB agonist to co-stimulate T cells. It is being studied in PD-L1-positive locally advanced or metastatic non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

GEN-1046, DuoBody-PD-L1×4-1BB

Drug type

Bispecific antibody

Targets

PD-L1 (CD274), 4-1BB (CD137) (TNFRSF9), PD-1 (PDCD1) (binding partner it blocks)

Mechanism

Immune activation, directed at PD-L1 (CD274) and 4-1BB (CD137) (TNFRSF9)

Pathways

PD-1/PD-L1 checkpoint blockade, 4-1BB costimulation of T-cell proliferation, survival and cytolytic activity

Therapy area

Oncology

Developer

Genmab (GMAB)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

UNII

H52ITZ9X9D

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on CD274 / TNFRSF9

Sources

• NCI Thesaurus

Updated Oct 11, 2026. Something wrong or missing? Report it on the GMAB page.